Pluristem Therapeutics Inc (PSTI)

[bluehorsesho]

Pioneering AFRRI research on the use of growth factors and cytokines as radiation countermeasures recently led to the first FDA approvals of medical countermeasures against ARS: Neupogen® (G-CSF) and Neulasta® (pegylated G-CSF).

https://www.usuhs.edu/afrri
 
Recent achievements by AFRRI researchers:

Development of a panel of seven efficacious radiation countermeasure candidates against acute radiation syndrome (ARS). These agents have low toxicity and practical routes of administration. They are ready for advanced development by other DOD agencies when resources become available. All are at Technology Readiness Level (TRL) 3 or above. This is the level for which AFRRI is funded (DOD S&T activities 6.2 and 6.3). One candidate (genistein or BIO-300) is at TRL 5, and another (5-AED) is at TRL 6.


https://www.usuhs.edu/afrri